Stockscreener 앱 받기
40.57
0.10%
0.04
시간 외 거래:
40.57
전일 마감가:
$40.53
열려 있는:
$40.84
하루 거래량:
2.40M
Relative Volume:
0.93
시가총액:
$8.37B
수익:
$2.10B
순이익/손실:
$402.17M
주가수익비율:
20.96
EPS:
1.9357
순현금흐름:
$403.87M
1주 성능:
-1.62%
1개월 성능:
+11.82%
6개월 성능:
-25.22%
1년 성능:
-18.06%
1일 변동 폭
$40.36
$41.16
1주일 범위
$39.36
$41.78
52주 변동 폭
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, NTRA, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
40.57 | 8.36B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
526.46 | 194.53B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
179.14 | 125.84B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
545.00 | 43.58B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
264.22 | 38.26B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
133.46 | 37.52B | 7.23B | 1.41B | 1.09B | 4.979 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-03-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-22 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-04 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-10-17 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-06-27 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-09-12 | 개시 | Robert W. Baird | Outperform |
| 2023-05-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-01-18 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-10-14 | 개시 | Redburn | Buy |
| 2021-07-14 | 다운그레이드 | Kepler | Buy → Hold |
| 2021-06-03 | 개시 | Goldman | Neutral |
| 2020-10-06 | 재개 | BofA Securities | Buy |
| 2020-09-28 | 업그레이드 | Kepler | Hold → Buy |
| 2020-08-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-08-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-08-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-08-14 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-12-26 | 재개 | BofA/Merrill | Underperform |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-11-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-11-14 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2019-11-14 | 업그레이드 | Kepler | Reduce → Hold |
| 2019-10-17 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | 다운그레이드 | Kepler | Hold → Reduce |
| 2019-10-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-08 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
Qiagen Nv 주식(QGEN)의 최신 뉴스
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen stock trades steady as diagnostics revenue grows and margin focus intensifies - Ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports earnings momentum - Ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports recent earnings - Ad-hoc-news.de
Qiagen stock holds firm as diagnostics demand supports revenue growth - Ad-hoc-news.de
Qiagen stock trades steady as recent results highlight margin resilience - Ad-hoc-news.de
Qiagen stock rises on recent results and market data - Ad-hoc-news.de
Baader Bank Aktiengesellschaft Buys New Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock trades steadily as diagnostics demand supports earnings and cash flow - Ad-hoc-news.de
Qiagen stock trades steadily as recent earnings and margin trends shape investor focus - Ad-hoc-news.de
Qiagen stock trades steady as investors weigh recent earnings and diagnostics demand - Ad-hoc-news.de
DekaBank Deutsche Girozentrale Takes $10.81 Million Position in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock holds as investors await fresh numbers - Ad-hoc-news.de
Qiagen stock trades steady as latest quarterly numbers highlight margin resilience - Ad-hoc-news.de
William Blair Initiates Qiagen NV(QGEN.US) With Hold Rating - Moomoo
Qiagen stock trades steadily as recent earnings and guidance frame valuation - ad-hoc-news.de
Qiagen stock steadies as investors weigh Q2 2025 earnings and diagnostics demand - ad-hoc-news.de
Qiagen stock rises on 2025 results and 2026 guidance - ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports earnings and cash flow - Ad-hoc-news.de
BlackRock Builds Significant Stake in Qiagen, Boosting Institutional Presence - The Globe and Mail
Citigroup Discloses 2.85% Stake in QIAGEN via AFM Filing - The Globe and Mail
Citigroup Reports 3.09% Indirect Stake in Qiagen via AFM Filing - The Globe and Mail
Goldman Sachs discloses 3.5% voting interest in Qiagen - The Globe and Mail
Qiagen stock holds ground as investors look to next earnings after steady 2024 revenue - ad-hoc-news.de
Allspring Global Investments Holdings LLC Has $100.21 Million Position in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock holds near recent levels as earnings metrics guide the story - ad-hoc-news.de
Qiagen stock holds steady as 2026 guidance and margins stay central - ad-hoc-news.de
Qiagen (QGEN) Investor presentation Summary - Quartr
Qiagen stock trades steady as Q1 2026 growth and margin resilience underpin outlook - ad-hoc-news.de
Qiagen stock trades steady as investors weigh Q1 2024 growth and margin trends - ad-hoc-news.de
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate - GlobeNewswire Inc.
Barings LLC Sells 77,747 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen stock trades steady as investors weigh recent earnings and molecular diagnostics demand - ad-hoc-news.de
Qiagen stock reflects steady diagnostics demand as earnings and cash flow support investment cycle - ad-hoc-news.de
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak - BioSpace
Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak - Investing.com UK
Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak By Investing.com - Investing.com South Africa
Qiagen Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak - marketscreener.com
Qiagen stock holds steady as diagnostics demand supports the long-term story - Ad Hoc News
QIAGEN N.V. to release Q2 2026 results on August 5 - scanx.trade
Berenberg Downgrades Qiagen Rating, Price Target Amid Rising Competition, Growth Concerns - Moomoo
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast - Yahoo Finance
Qiagen stock holds steady as investors track the business - ad-hoc-news.de
Berenberg Bank Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $45.74 - Moomoo
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe - BioSpace
Qiagen Is Attracting Billion-Dollar Takeover Interest! - Smartkarma
Qiagen launches bloodstream infection test panel in Europe By Investing.com - Investing.com India
USF157.USD Bond Profile — Key Metrics - TradingView
Enterprise value to revenue forward of Qiagen N.V. – NYSE:QGEN - TradingView
Qiagen (QGEN) Unveils New Bloodstream Infection Testing Panel in Europe - GuruFocus
Qiagen Nv (QGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.95%
자본화:
|
볼륨(24시간):